Trabectedin in patients with advanced soft tissue sarcoma: A retrospective national analysis of the French Sarcoma Group

European Journal of Cancer

Volumn 51, Issue 6, 2015, Pages 742-750

  Le Cesne, Axel ^a   Ray Coquard, Isabelle ^b   Duffaud, Florence ^c   Chevreau, Christine ^d   Penel, Nicolas ^e   Bui Nguyen, Binh ^f   Piperno Neumann, Sophie ^g   Delcambre, Corinne ^h   Rios, Maria ⁱ   Chaigneau, Loic ^j   Le Maignan, Christine ^k   Guillemet, Cecile ^l   Bertucci, François ^m   Bompas, Emmanuelle ⁿ   Linassier, Claude ^o   Olivier, Thimotée ^p   Kurtz, Jean Emmanuel ^q   Even, Caroline ^a   Cousin, Philippe ^b   Yves Blay, Jean ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE LÉON BÉRARD   (France)

^c TIMONE HOSPITAL   (France)

^d INSTITUT CLAUDIUS REGAUD   (France)

^e CENTRE OSCAR LAMBRET   (France)

^f INSTITUT BERGONIÉ   (France)

^g INSTITUT CURIE   (France)

^h CENTRE FRANÇOIS BACLESSE   (France)

ⁱ CRLCC de Lorraine Alexis Vautrin   (France)

^j UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^k SAINT LOUIS HOSPITAL   (France)

^l CRLCC Henri Becquerel   (France)

^m INSTITUT PAOLI CALMETTES   (France)

ⁿ UMR INSERM U892 CNRS 6299   (France)

^o UNIVERSITY HOSPITAL OF TOURS   (France)

^p CENTRE VAL D AURELLE   (France)

^q UNIVERSITÉ DE STRASBOURG   (France)

more..

Author keywords

Advanced; Metastasis; RetrospectYon; Sarcoma; Trabectedin

Indexed keywords

TRABECTEDIN; 1,3 DIOXOLANE DERIVATIVE; ALKYLATING AGENT; TETRAHYDROISOQUINOLINE DERIVATIVE;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; CHILD; CONTINUOUS INFUSION; DEATH; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; FOLLOW UP; FRANCE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SOFT TISSUE SARCOMA; UNSPECIFIED SIDE EFFECT; DISEASE FREE SURVIVAL; MIDDLE AGED; SARCOMA; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; CHILD; DIOXOLES; DISEASE-FREE SURVIVAL; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SARCOMA; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84925373086     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.01.006     Document Type: Article

References (23)

1. M.A. Clark, C. Fisher, I. Judson, and J.M. Thomas Soft-tissue sarcomas in adults N Engl J Med 353 2005 701 711
2. P.G. Casali, and J.Y. Blay Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 21 2010 v198 v203
3. N.J. Carter, and S.J. Keam Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer Drugs 70 2010 355 376
4. M. D'Incalci, and C.M. Galmarini A review of trabectedin (ET-743): a unique mechanism of action Mol Cancer Ther 9 2010 2157 2163
5. P. Allavena, M. Signorelli, and M. Chieppa Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production Cancer Res 65 2005 2964 2971
6. G. Germano, R. Frapolli, and M. Simone Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells Cancer Res 70 2010 2235 2244
7. G. Germano, R. Frapolli, and C. Belgiovine Role of macrophage targeting in the antitumor activity of trabectedin Cancer Cell 23 2013 249 262
8. A. Le Cesne, J.Y. Blay, and I. Judson Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial J Clin Oncol 23 2005 576 584
9. A. Yovine, M. Riofrio, and J.Y. Blay Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients J Clin Oncol 22 2004 890 899
10. R. Garcia-Carbonero, J.G. Supko, and J. Manola Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy J Clin Oncol 22 2004 1480 1490
11. R. Garcia-Carbonero, J.G. Supko, and R.G. Maki Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study J Clin Oncol 23 2005 5484 5492
12. J.Y. Blay, A. Italiano, and I. Ray-Coquard Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program BMC Cancer 13 2013 64
13. B.L. Samuels, S. Chawla, and S. Patel Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study Ann Oncol 24 2013 1703 1709
14. J. Fayette, H. Boyle, and S. Chabaud Efficacy of trabectedin for advanced sarcomas in clinical trials versus compassionate use programs: analysis of 92 patients treated in a single institution Anticancer Drugs 21 2010 113 119
15. G.D. Demetri, S.P. Chawla, and M. von Mehren Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules J Clin Oncol 27 2009 4188 4196
16. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 2000 205 216
17. American Society of Clinical Oncology (ASCO) Update of recommendations for use of hematopoetic colony-stimulating factors: evidence-based clinical practice guidelines J Clin Oncol 14 1996 1957 1960
18. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
19. M. Van Glabbeke, J. Verweij, I. Judson, and O.S. Nielsen Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas Eur J Cancer 38 2002 543 549
20. European Medicines Agency (EMA). Yondelis® - Product information. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000773/WC500045832.pdf. Accessed March 2014; 2013 [accessed June 2012].
21. J.Y. Blay, P. Casali, A. Nieto, A. Tanovic, and A. Le Cesne Efficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcoma Future Oncol 10 2014 59 68
22. A. Le Cesne, A. Yovine, and J.Y. Blay A retrospective pooled analysis of trabectedin safety in 1132 patients with solid tumors treated in phase II clinical trials Invest New Drugs 30 1 2012 193 202
23. A. Le Cesne, J.Y. Blay, and T. Ryckewaert Benefit of maintenance therapy with trabectedin (T) beyond the 6 first cycles: results of a prospective randomized phase II trial comparing interruption vs. continuation of T in patients (pts) with advanced soft tissue sarcoma (ASTS): an update Ann Oncol 25 2014 Abstract 1414O